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Reversal of vinblastine transport by chlorpromazine in
membrane vesicles from multidrug-resistant human
CCRF-CEM leukaemia cells
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Summary The mechanism of action of 2-chlorpromazine (2-chloro-10-(3-dimethylaminopropyl)-phenothiazine) as a reversal agent for
P-glycoprotein-mediated multidrug resistance was investigated using inside out-orientated membrane vesicles prepared from vinblastine-
resistant human CCRF-CEM leukaemia cells (VBL,,,). 2-Chlorpromazine (10 tM) completely inhibited ATP-dependent P-glycoprotein-
mediated vinblastine accumulation in the vesicles. Whereas in the absence of added ligands VBL transport was described by a hyperbolic
function of vinblastine concentration, in the presence of 2-chlorpromazine vinblastine transport was a sigmoidal function. 2-Chlorpromazine
was shown previously [Syed SK. Christopherson RI and Roufogalis BD (1996) Biochem Mol Biol Int39: 687-696] to be actively transported
into vesicles from multidrug-resistant cells. Colchicine (10gum) and phenoxybenzamine (10 UM) blocked vinblastine transport but had no effect
on 2-chlorpromazine transport into vesicles. The results were consistent with a two-state concerted model in which P-glycoprotein exists in
two conformational states. PA and PB. where 2-chlorpromazine is transported by the conformer, PA' and vinblastine by the conformer. PB In
the presence of 2-chlorpromazine. the conformer PA predominates and vinblastine transport is inhibited. Addition of 2-chlorpromazine during
the steady state of vinblastine accumulation blocked uptake and resulted in enhanced vinblastine effiux from the vesicles. The findings were
similar when vinblastine was added at the steady state of 2-chlorpromazine transport. We propose a minimal kinetic model whereby in these
preloaded vesicles the complex W.PA.CC is formed, where two intemal binding sites of P-glycoprotein (PA) are occupied by vinblastine (V)
and the two extemal sites are occupied by 2-chlorpromazine (C). When the two binding sites on both the inside and outside of P-glycoprotein
are saturated with ligands vinblastine is effluxed at a very rapid rate. and vice versa when vesicles are preloaded with 2-chlorpromazine and
vinblastine is added outside. These unexpected observations and the concerted model developed provide an altemative mechanism of action
for reversal agents that sensitize multidrug-resistant cancer cells to anti-cancer drugs.
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A common clinical problem in the treatment ofcancer is the dev-el-
opment ofresistance to multiple chemotherapeutic agents. Tumour
cells grown in the presence of a single anti-cancer drug mar
become resistant to a w-ide range of structurallx dissimilar drugs
(FOjo et al. 1985: Arias. 1990-. In cell culture. this phenomenon.
known as multidrug resistance (NIDR). has been show-n to be due
to oxerexpression of the MXDR-1 gene. which encodes P-glycopro-
tein (Gottesman and Pastan. 1988). P-glycoprotein is a membrane-
associated M1-'-dependent ATPase and uses the energy of ATP
hxdrolI-sis to pump drugs out ofcells. thereby reducing their intra-
cellular concentrations and hence their c-totoxicities (Hamada and
Tsuruo. 1988).
The mechanism by w-hich P-glycoprotein. a 170- to 180-kDa
protein. recognizes and extrudes a large number of diverse
compounds is not yet clear. Howxever. recent wvork using different
combinations ofdrugs to studv drug, binding, to P-glxcoprotein. or
drua efflux mediated by the protein. suggests that there may be
more than one site on P-gl^-coprotein to which substrates bind and
are subsequently transported across the membrane (Tamai
and Safa. 1991: Ferr- et al. 1992: Spoelstra et al. 1992: Malkhandi
et al. 1994).
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Narious compounds reverse MIDR and make cells sensitixve to
anti-cancer drugs. These 'chemosensitizers' include calcium
channel blockers (e.g. -erapamil: Tsuruo et al. 1982). calmodulin
antagonists (e.g. phenothiazines: Ford et al. 1989). the anti-
arrhvthmic agent quinidine (Hofsli and Nissen-NMever. 1990) and
the immune suppressor cyclosporin A (Nooter et al. 1989). These
compounds are not only xvery different from each other in struc-
ture but also have quite different effects on cellular physiology
and are often cytotoxic on their oi-n. Verapamil is a competitive
inhibitor with respect to some substrates of P-gl coprotein
(Sehested et al. 1990) but is non-competitixe w-ith others (Pereira
et al. 1994). Howexer. the mechanism of action of the pheno-
thiazines. such as 2-chlorpromazine (2-CPZ) and trifluoperazine.
is not clear.
Elucidation of the mechanism of rex ersal ofMDR by different
chemosensitizers is important for the dexvelopment of newi
chemotherapeutic strategies to oxercome this resistance. We
hax e prex iously reported drug transport studies in inside-out
membrane xesicles prepared from human CCRF CEM-VBL
multidrug-resistant cells (Syed et al. 1993. 1996). Membrane
x-esicles offer a unique s5ystem for studyving the mechanisms
bv which different chemosensitizers exert their effects on
P-glycoprotein-mediated drug transport. Using this system. we
report here studies on the mechanism of action of 2-CPZ. a
potential chemosensitizer. and a closely related structural
analogyue (Ford et al. 1989).
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MATERIALS AND METHODS
Chemicals
[lH]Vmblastine (['H]VBL: 11.7 Ci mmol-') was obtained from
Amersham Intemational. Arlington (UK): verapamil. ATW AMP.
creatine phosphate. creatine phosphokinase and RPMI-1640
cell culture medium were from the Sigma Chemical Company.
St Louis. MO. USA: and 2-[`H]chlorpromazine (2-[PHICPZ:
30 Ci mmol-1) was purchased from NEN/Du Pont. Sydney.
Australia. Fetal calf serum was obtained from the Commonwealth
Serum Laboratories. Parkville. Australia. All otherchemicals were
of analytical reagent grade. 4-Chlorpromazine was a gift from
Dr AR Green. Smith. Kline and French. Montreal. Canada.
Cell culture and membrane vesicle preparation
Human CCRF-CEM leukaemia cells and the vinblastine-resistant
mutant cell line. CEMIVBL0OOO. were grown in 2-1 cultures of
RPMI-1640 medium containing 10% (v/v) fetal calf serum and
50 jg ml-' gentamicin. The method ofmembrane preparation was
essentially as described previously (May et al. 1988: Syed et al.
1993). Cells were harvested at a density of 8 x 10-i cells ml-'.
washed three times with phosphate-buffered saline and suspended
in 5 volumes of 'cavitation buffer' (10 mm Tris-HCI. pH 7.4.
250 mM sucrose. 0.2 =m calcium chloride. 10 m,rm leupeptin and
1 mm phenylmethylsulphonyl fluoride). They were then disrupted
by cavitation under nitrogen pressure at 500 psi for 15 min at
4°C. EDTA was added to the cell homogenate to a final concen-
tration of 1 mM and the homogenate centrifuged at 1000 g for
10 min to remove cellular debris. The supematant was saved and
the pellet was disrupted again in 2 volumes ofcavitation buffer at
500 psi for 10 min. After centrifugation at 1000g for 10 min, the
two supernatants were pooled and layered over 35% (w/v)
sucrose in 10 mm Tris-HCl. pH 7.4 and centrifuged at 16 000g
for 50 min Vesicles at the supematant-sucrose interface were
collected, diluted in 10 mm Tris-HCl, pH 7.4 and 250 mm sucrose
(buffer A) and centrifuged at 105 000 g for 1 h. The pellet was
then suspended in buffer A and frozen immediately at -70°C.
Drug accumulation by membrane vesicles
Accumulation of VBL and 2-CPZ by membrane vesicles
was measured essentially as described previously (Horio et al,
1988: Syed et al. 1993. 1996). Briefly. 20 jl ofvesicles (5 mg pro-
tein ml-') was added to 30 jl of ATP-containing buffer (10 mM
Tris-HCl. pH 7.5. 1 mM ATP. 10 mm magnesium chloride. 10 mm
creatine phosphate. 250 mm sucrose and 100 jg ml-' creatine
phosphokinase) at 25°C. The reaction was started by the addition
of 50 jl of reaction medium containing 120 n-m [3H]VBL or
2-[3H]CPZ in buffer A. At appropriate times the reaction was
terminated by addition of 4 ml of ice-cold buffer A and the
mixture immediately applied to cellulose acetate filters
(0.45 m. Microfiltration System. Japan) under vacuum. The
filters were washed once with buffer A. dried and counted in 6 ml
of scintillation cocktail (Emulsifier-Safe. Packard, USA). Non-
ATP-dependent association ofthe radiolabelled drug with the vesi-
cles and filter was determined with incubation medium lacking
ATP and the ATP regenerating system orcontaining AMP instead.
These counts were subtracted from the total counts (in the pres-
ence of ATP) to give ATP-dependent specific uptake of the drug.
Plots presented are representative of three separate experiments
carried out in duplicate.
Calcium accumulation experiments
Calcium uptake by membrane vesicles was measured essentially
as described by Shibata and Ghishan (1990). Briefly. membrane
vesicles were incubated at 37°C in reaction mixture (final volume
0.1 ml) containing 100 mm mannitol. 100 mm potassium chloride.
10 mm Tris-HCI buffer(pH 7.4). 1 m.ouabain and0.1 Thm [4-Ca]-
calcium chloride (10 jCi mmol-1). Transport was initiated by
adding 3 mm ATP, and after 20 min the reaction medium was
vacuum filtered to separate free calcium from the vesicles. as
described above. The effect of alamethicin. a membrane-
permeabilizing agent. and 2-CPZ on calcium uptake was studied.
Analysis of data
Rates of uptake of ['H]VBL into vesicles were determined by
linear regression of the slope of VBL accumulation determined at
2, 4 and 6 min. These rates (v) as functions ofsubstrate concentra-
tions (S) were then fitted to the following velocity equations by
non-linear regression using the program SigmaPlot (Version 4.16.
Jandel Scientific, USA).
11= Vrr-A[S]
Krn + [IS
V [Sin
11 = max
K+ [S]n
Vm [SI (I + [SIVK )
K,- (L + (1 + [SI/KX0)
(1)
(2)
(3)
Equation 1 is the Michaelis-Menten equation. equation 2 is the
Hill equation and equation 3 describes the concerted model of
Monod et al (1965) where the acceptor (P-glycoprotein) has two
independent ligand (vinblastine)-binding sites (see Scheme 1).
RESULTS
Effect of 2-chlorpromazine on vinblastine accumulation
Membranes prepared from multidrug-resistant human leukaemia
cells (CCRF-CEM/VBL1O) by high-pressure cavitation and
differential centrifugation form a mixture of inside-out and right
side-out membrane vesicles (Syed et al. 1993). Inside-out orien-
tated vesicles actively accumulate VBL in a time-dependent
manner. Greater than 90% ofthe total uptake was ATP dependent.
To understand the MDR-modulating mechanism of 2-CPZ. we
studied its effect on VBL accumulation by membrane vesicles.
Figure 1 shows ATP-dependent accumulation from 60 mnm VBL by
the vesicles. Accumulation was initially linear and reached a
steady state at 10-15 min. Addition of 10 jim 2-CPZ before the
addition ofATPeffectively inhibited VBL accumulation. Addition
of 2-CPZ (10 jM) after the steady-state level of VBL had been
reached resulted in efflux ofVBL from the vesicles at a rate more
rapid than expected from the apparent initial rate of accumulation
(Figure 1). had the only effect of2-CPZ been to stop VBL uptake.
The VBL accumulation was prevented 10 min after 2-CPZ addi-
tion (Figure 1) and beyond (results not shown).
To further investigate this effect. sodium vanadate (100 jM)
was used to inhibit the Mg2+-ATPase activity of P-glycoprotein
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Figure 1 Inhibitory effect of 2-CPZ on VBL accumulation by membrane
vesicles from drug-resistant cells. Uptake of 60 nM [3H]VBL was measured in
vesicles in the presence of ATP and an ATP-regenerating system. 2-CPZ
(10 jiM) was added either at the start of the reaction (-) or after the steady
state had been reached (V). The reaction medium (100 il) contained 10 mm
Tns-HCI (pH 7.4). 250 mm sucrose. 3.3 mm MgCl2. 3.3 mm creabne
phosphate. 100 ug ml- creabne kinase and 100-125 ggrmembrane protein.
Values of [H1VBL accumulation in the absence of ATP were subtracted from
the total accumulation at each time point to determine the ATP-dependent
accumulation
(Gottesman and Pastan. 1988). both alone and in the presence of 2-
CPZ. Note that the ATP-binding domains of P-glxcoprotein are on
the outside of inside-out -esicles. The rate of efflux of ['H]VBL
induced bN stoppinc transport with vanadate wvas lower than that
induced by 10 pi 2-CPZ (Figure 2). In the presence ofboth 2-CPZ
and vanadate. the efflux of ['H]VBL was intermediate between
that with either acent alone. These results suggest that the rapid
efflux of VBL in the presence of 2-CPZ was induced by 2-CPZ
addition. with a requirement for ATP.
Effect of 2-CPZ on calcium permeability in membrane
vesicles
To see if the effect of 2-CPZ on inducing rapid ['H]VBL efflux
w as due to disruption or non-specific permeabilization of
membrane vesicles. we examined the effect of 2-CPZ on calcium
uptake and efflux %-ia the membrane Ca+-ATPase. Alamethicin
was used as a control permeabilizing agent as it forms pores in
membrane vesicles and makes them leak-x to ions and small mole-
cules (McLaugyhlin and Eisenberg. 1975). As expected. alame-
thicin (20 jgL ml-') prevented accumulation of -'Ca' inside the
Vesicles (Firure 3). 2-CPZ (10 gt\o. however. had no effect on
calcium accumulation %-xhether added before the addition of ATP
or after steadv-state Ca' uptake had been reached. showing that
under the conditions of the experiment used in the VBL uptake
studies 2-CPZ does not non-specifically permeabilize the
membrane Xesicles (Figure 3).
Effects of 2-chlorpromazine on the kinetics of
vinblastine transport
The dependence of initial [IH]VBL uptake by inside-out -esicles on
the concentration ofextemal VBL w-as fitted by non-linear regression
Figure 2 Effect of vanadate on VBL accumulation. Reaction conditions
were the same as described in Figure 1. Sodium vanadate (100 gM) was
added at 15 min separately ( ) or with 10 M 2-CPZ (-). Also shown is the
effect of 10 jM 2-CPZ alone (V)
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Figure 3 Effect of 2-CPZ on Ca2--ATPase-mediated calcium accumulation
by membrane vesicles. Calcium accumulation by membrane vesicles was
measured (see Matenals and methods) in the absence and presence of
alamethicin (20 gg mlt) and 2-CPZ (10 gM). 2-CPZ (10 gm) was also added
after the steady state of calcium accumulation had been reached
to equations 1. 2 and 3. The best fit w-as obtained for the
Michaehis-Menten equation (equation 1 ) xith parameter values
of K = 70.8 ±24.7 nw and =0.48 + 0.07 pmol min-' mg
m mr"x Z:
membrane protein-' (Figure 4A). The curve for VBL uptake in the
presence of 5 jim 2-CPZ (see data in Figure 4B was fitted to the Hill
equation (equation 2). to vield a Hill coefficient of 1.23. consistent
%%ith more than one binding site for VBL on P-glycoprotein. Data for
Fiaures 4A and B were also fitted to equation 3 describinb the
concerted model (see Scheme 1). yielding parameter xalues for
Figure 4A of K = 70.6 nM\.V = 0.48 pmol mni-' mg membrane
protein-' and L = 1.70 x 10-". and for Figure 4B of K, = 456 n-\t.
V = 1.70 pmol mmn-I mg membrane protein-' and L = 0.049. The
simulated curves through the data of Figures 4A and B were gener-
ated using these parameter -alues and equation 3. The increase in the
allosteric equilibnrum constant. L,. from 1.70 x 10-8 to 0.049 in the
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Figure 5 Effect of 4-CPZ on [3HYVBL accumulation by membrane vesicles.
4-CPZ (10 uM) was added either at the start of the incubation (-) or after the
steady state had been reached (V). Control [3HIVBL accumulation was
determined as for Figure 1
in rapid VBL efflux (results not shosnh. Ahen 4-CPZ w-as added
from the start of the incubation. it inhibited VBL transport
similarix to '-CPZ (cf. Finures 5 and 1).
Effects of coichicine and phenoxybenzamine on
vinblastine and 2-chlorpromazine accumulation
0 100 200
[3HJVBL (nm)
Figure 4 Effects of 2-CPZ on the initial uptake rate of \
vesicles as a function of extravesicular VBL concentratic
rates were determined at the indicated concentrations ol
time points as described in Materials and methods. A Cc
CPZ. Data for both experiments were fitted to the Micha
equations and the equation describing a Concerted Mod
Matenals and methods (equations 1. 2 and 3) and Resul
values obtained from the Concerted Model were used to
through the experimental data for A and B
We have shown that '-CPZ is actively transported bv these inside-
out vesicles (Sved et al. 1996). VBL (10 I.tm) fullx inhibited 2-CPZ
accumulation when added at the be-innin, of the incubation and.
390 400 when it was added after the steadv-state for 2-CPZ accumulation
had been reached. it induced efflux of 2-CPZ. which w-as more
rapid than expected from the initial rate of uptake of 2-CPZ (see
VBL by membrane Syed et al. 1996). Thus. VBL and 2-CPZ have reciprocal effects
in. Initial uptake on the transport of each other. By contrast 10gr\t colchicine. a P-
f[Hr.BLfropu
three 5ly coprotein substrate in these Xesicles (unpublished observa-
elis-Menten and Hill tions). inhibited VBL uptake by approximately 50% but had no
Wl,as described in effect on 2-CPZ transport (Table 1). Similarly. 10 m phenoxv- fts. The paramneter
draw
The parameter benzamine. a calmodulin antanorist like 2-CPZ. did not inhibit 2-
CPZ transport. whereas at this concentration it inhibited VBL
transport by approximatelv 70%7c (Table 1).
presence of 2-CPZ is consistent sith an increase in the proportion of
a conformer of P-l coprotein (P) that does not bind VBL (see
Scheme 1). The apparent increase in V is also of interest and is
under further inxestioation.
Effect of 4-chlorpromazine on vinblastine accumulation
A different behaviour was observed with 4-CPZ. an analocgue of
2-chlorpromazine in which the chlonrne on aromatic ngn C of the
tricyclic structure is at position 4 rather than 2. When 4-CPZ was
added at the steady state of ['H]VBL uptake. the accumulated
VBL effluxed rapidly' but then the intravesicular [ H]VBL concen-
tration retumed to the original steady-state level (Figure 5). A
second application of 4-CPZ at the new steady state again resulted
DISCUSSION
MDR acquired during chemotherapy may in some cases be
attributed to overexpression of P-glOcoprotein. '-hich acti'ely
extrudes anti-cancer drugs from cells. The P-glwcoprotein struc-
ture consists of tm o halves. each with six transmembrane
domains and one ATP bindin2 site (Azzaria et al. 1989:
Rosenbera et al. 1997). There is evidence that hvdrol1sis of ATP
at both sites is required for substrate transport (see Stein. 1997).
Mlost of the compounds transported Xia P-glycoprotein are
lipophilic and cationic at physiological pH (Beck and Qian.
1992). This broad specificitx has suggested that lipophilic
compounds Aith low- toxicitV could be used to saturate and
thereby functionally inactix ate P-glvcoprotein. enablincg the
British Joumal of Cancer (1998) 78(3). 321-327
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Table 1 Inhibitory effects of drugs on vinblastne (VBL) and chlorpromazine
(2-CPZ) accumulation by membrane vesicles The effects of 10 gm each of
VBL. coichicine or phenoxybenzamine on VBL and 2-CPZ transport were
studied. The drugs. dissolved in dimethyl sulphoxide. were added to vesicles
in the reaction medium and incubated for 10 min before the addition of 60 nm
[3;HVBL or [3H]CPZ to start transport. as described in Materials and methods.
The final concentration of dimethyl sulphoxide never exceeded 100 (v/v).
Values for per cent inhibition are mean ± s.d. of three experiments
Drug Per cent inhibition of accumulation
VBL 2-CPZ
Vinblastine 100 100
Colchicine 45.5 - 2.8 0
Phenoxybenzamine 70.8 ± 8.0 5.0 + 0.9
retention of cvtotoxic drugs w-ithin cells. How-esver. most of the
chemosensitizers used so far. although effective in inhibiting P-
glycoprotein-mediated transport. has-e had toxic side-effects at
the concentrations needed for the inhibition (Ford et al. 1989).
Reversal of drug resistance w-ith reduced in vivo toxicitx micht
be achieved with pharmacologically inactive analogues of the
anti-cancer drugs or a combination of two or more chemosensi-
tizing agents. as their ability- to reverse drug resistance mav be
additive or synergistic (Stein. 1997). Rexersal of MDR might be
more effective clinicallx if the drugs used acted by different
mechanisms or had different bindine sites on P-glxcoprotein.
The present studies wxere carried out to explore these possibilities
in inside-out membrane vesicles prepared from multidrug-resis-
tant human CCRF-CEM leukaemia cells. This vesicle prepara-
tion offers a unique system for examinin, the kinetics of drug
transport free of many of the interactions that could affect the
kinetics of drug transport in intact cells (see Stein. 1997).
2-CPZ (10 Im) blocked the initial accumulation of ['H]VBL
by vesicles almost completely (Figure 1. WAhen 2-CPZ (10 jrm)
xwas added at the steady state of [H]VBL accumulation (after
10-15 min). VBL was effluxed from the vesicles. consistent Awith
inhibition by 2-CPZ of ['H]VBL uptake. However. the rate of
efflux of VBL was considerably more rapid than the initial rate
of accumulation. being 80' complete within 5 min after 2-CPZ
addition. A number of possible mechanisms for this unexpected
effect w-ere considered. Phenothiazines are membrane-actiVe
agents that can disrupt membrane structure and lead to cell lysis
and increased membrane permeability (Saito et al. 1989).
How-ever. the rapid [VH]VBL efflux following 2-CPZ addition
did not appear to be due to a general increase in membrane
permeability. as in a parallel experiment addition of the same
concentration of 2-CPZ (10 P%\o to vesicles at steady state of
'Ca> accumulation catal-sed by the Ca:--pump ATPase did not
cause 4'Ca' to efflux from the vesicles (Figure 3). This result
suggests that under the conditions used the effect of 2-CPZ is
selecti-e for the P-l-coprotein-mediated transport process.
Similar rapid effluxes A-ere seen when unlabelled VBL A-as
added at the steady state for accumulation of ['H]VBL (unpub-
lished results) or 2-['H]CPZ (Syed et al. 1996). The pathway for
VBL efflux from the inside-out vesicles. equixalent to influx in
riaht side-oriented cancer cells. is not know-n. The rapid efflux of
['H]VBL wxas specific to P-glycoprotein ligands (unlabelled
VBL or 2-CPZ). as blockinc ofvinblastine transport by complete
inhibition of the ATPase activitv of P-glycoprotein with sodium
-anadate induced [IH]VBL efflux at a rate corresponding to the
initial rate of VBL accumulation (Figure 2). Ahen 2-CPZ was
added with x-anadate. a rate of efflux intermediate betv een those
observed after addition of 2-CPZ and vanadate singlx was
observed (Figure 2).
Data for the initial accumulation of VBL or 2-CPZ by P-glxco-
protein by inside-out *-esicles and the effects of inhibitors of druc
accumulation are consistent with the concerted model ofMonod et
al (1965). in which P-glx coprotein has tmo binding sites for drucs
on the outside of vesicles (consistent svith a Hill coefficient of
1.23) and two on the inside. These pairs of sites have a similar
affinity for the drug. either both hiah or low. hence the term
.concerted model'. We propose that P-glxcoprotein exists in two
conformational states. P, and PB* 2-CPZ is bound and transported
by PA. whereas VBL is not. and PB binds and transports VBL but
not CPZ. The various species of P-glxcoprotein present initiallx
are show-n in Scheme 1.
PA -%'% PA.C -===m
Li $
PA.CC
Scheme 1
P -~ 'P.V PBVV B B' B K,% Kt
>-here. for example. P_.CC and PB'.VV are the two conformers of
P-glycoprotein with 2-CPZ and VBL. respectively. bound at tx-o
sites on the outer side of the xesicle; KC and Kl, are dissociation
constants for the bindinc of 2-CPZ and VBL. respectively. and L
is the allosteric equilibrium constant (equation 4).
Li = [PA]/IPB] (4)
The saturation curve for VBL transport as a function of the
external concentration of VBL follows a hyperbolic function
(Figure 4A) and it is therefore concluded that in the absence of
ligands a significant proportion ofP-glycoprotein is the conformer
PB In the presence of2-CPZ (5 j.mx). the proportion ofP-glycopro-
tein asPA is increased and the saturation curve for VBL uptake as
a function of VBL concentration becomes sigmoidal (Figure 4B).
'When the VBL concentration increases. the proportion of PB
capable of mediatince VBL uptake increases. generating a
siamoidal saturation curve. The Hill coefficient obtained in the
presence of5 g-xt 2-CPZ. n = 1.23. is consistent w-ith interaction of
VBL with two external sites on P-glX7coprotein of inside-out vesi-
cles. This concerted model can be extended to the subsequent
steady state w-here VBL has accumulated in vesicles and '-CPZ is
then added. inducing a ver- rapid efflux of VBL from the
preloaded vesicles (Figure 1). We propose that in preloaded vesi-
cles the tuo internal binding, sites of P-l coprotein (facingy the
vesicle lumen) are occupied by VBL at saturating internal concen-
trations. indicated by the ligands )VV) written to the left of the
acceptor. P,:
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VV.P VV.PgC V- V.Pcc
Kc Kc
L
W^PBOV - - VW.P .vv
Scheme 2
where the saturated P-glycoprotein complex. VV.P .CC. with
VBL bound on the inside and 2-CPZ bound on the outside. enables
the very rapid efflux of VBL observed from the steady state when
2-CPZ is added (Figure 1). The converse is also true: there is very
rapid efflux of 2-CPZ accumulated in vesicles to a steady state
when VBL is then added (see Syed et al. 1996), because of
formation of the saturated complex. CC.PB.W. which rapidly
effluxes 2-CPZ.
There are several reasons why P-glycoprotein may exist in two
conformational states with specificity for VBL orCPZ. It has been
proposed that P-glycoprotein is able to pump out hydrophilic
drugs from the intemal aqueous cytosol of cells (see Higgins and
Gottesman. 1992) and also. lipid-soluble drugs may be pumped
out from the lipid bilayer (Rosenberg et al, 1997). The reason for
putative differential transport pathways is not known. P-glyco-
protein may have one conformational state. PA which binds and
pumps classes of drugs such as 2-CPZ from one site in the lipid
bilayer into vesicles and a second conformational state. PB. which
binds and pumps drugs such as VBL from a different lipid phase
into vesicles. All the saturated complexes of P-glycoprotein
(VV.P,,.CC. CC.PBWV and VV.PB.VV) would rapidly efflux
the internal ligand of the inside-out vesicles (on the left) to the
exterior. We have found that verapamil has similar inhibitory
effects on VBL uptake to 2-CPZ: it also induces the rapid efflux of
VBL from preloaded vesicles (cf. Figure 1) and sigmoidality in the
saturation curve for VBL uptake as a function of VBL concen-
tration (cf. Figure 4B: data not shown).
The dataofTable 1 provide furtherevidence that P-glycoprotein
may exist in two conformational states. Colchicine and phenoxy-
benzamine are effective inhibitors of VBL uptake by vesicles.
but at the same concentrations have little effect on the uptake of
2-CPZ. There is evidence for distinct sites on P-glycoprotein for
substrates and chemosensitizers. Whereas vincristine, VBL. vera-
pamil and reserpine effectively inhibit binding of a photoaffinity
analogue of VBL and azidopine to P-glycoprotein. inhibition by
the phenothiazines, 2-CPZ and trifluoperazine. and by chloro-
quine. is poor (Safa et al. 1986; Akiyama et al, 1988).
The concerted, two-state model of Schemes 1 and 2 is also
consistent with the inhibition of VBL accumulation by vanadate
(Figure 2). Addition of vanadate to vesicles that had accumulated
VBL to the steady-state level resulted in efflux ofVBL at a similar
rate to the initial accumulation rate as a result of inhibition of the
ATPase activity ofP-glycoprotein (Figure 2). We conclude that the
saturated complexes ofP-glycoprotein can only rapidly efflux the
intemal ligand with concurrent ATPase activity. The finding that
P-glycoprotein acts efficiently as a drug -efflux pump with low but
not high concentrations of anti-cancer agents outside target cells
(Miyamoto et al. 1996) might be accounted for by rapid influx of
the anti-cancer agents through the pump. consistent with data
presented here, or by inhibition of the efflux pathway in intact
cells when extemal sites are saturated.
The model can also account for the transitory inhibition ofVBL
accumulation induced by addition of 4-CPZ at steady state
(Figure 5). When 4-CPZ is added at the steady state for VBL trans-
porL the complex VV.P,,CC would be formed, with consequent
rapid efflux of VBL (Figure 5). However, with the loss of VBL
from inside the vesicle upon its rapid efflux. the complex PA.CC
would predominate and if the dissociation constant Kc were
higher for 4-CPZ than for 2-CPZ, VBL could bind to form PBNV.
with dissociation ofthe 4-CPZ. At this stage. the transport ofVBL
would resume. as shown in Figure 5. This effect should be
reversed on a second addition of4-CPZ, as was indeed found to be
the case. Ford et al (1989) have shown the importance ofsubstitu-
tion at the 2-position ofring C ofthe phenothiazines foranti-MDR
activity and demonstrated that 2-CPZ has ahigher MDR ratio than
4-CPZ. The significance of this oscillatory behaviour of the
P-glycoprotein pump remains to be determined.
The minimal concerted two-state model summarized in
Schemes 1 and 2 is consistent with the datapresented in this paper.
Equation 3 derived from the concerted model proposed here for
P-glycoprotein (Schemes 1 and 2) was able to satisfactorily simu-
late the data shown for VBL uptake in the absence or presence of
2-CPZ (Figures 4A and B). but in the absence of 2-CPZ the data
was well approximated by a simple hyperbolic function (equation
1. Fig. 4A). We propose to further test and refine this model using
a continuous, real-time assay rather than the stopped-time
radioassay used here. This model provides an alternative explana-
tion for the mechanism of action of reversal agents that sensitize
multidrug-resistant cancer cells to anti-cancer drugs. A non-toxic
reversal agent could be administered first to the patient to bind to
internal sites in cells of the right side-out P-glycoprotein. A cyto-
toxic drug such as vinblastine subsequently administered could
then rapidly enter multidrug-resistant cells with high levels of P-
glycoprotein via saturated complexes formed because of internal
binding ofthe reversal agent. Thus. all cells expressing high levels
of P-glycoprotein would be selectively exposed to the subse-
quently administered anti-cancer drug.
ABBREVIATIONS
MDR. multidrug resistance: VBL, vinblastine: 2-CPZ. 2-chlor-
promazine (2-chloro-1-(3-dimethylaminopropyl)-phenothiazine)-
4-CPZ, 4-chlorpromazine (4-chloro-1043-dimethylaminopropyl)-
phenothiazine).
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